# (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

> **NCT05607004** · PHASE2 · RECRUITING · sponsor: **Atossa Therapeutics, Inc.** · enrollment: 87 (estimated)

## Conditions studied

- Breast Neoplasms
- Invasive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** (Z)-endoxifen
- **DRUG:** goserelin

## Key facts

- **NCT ID:** NCT05607004
- **Lead sponsor:** Atossa Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-14
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607004, "(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05607004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*